Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration
Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year o...
Gespeichert in:
| Veröffentlicht in: | Ophthalmologica (Basel) 2016-01, Vol.236 (4), p.201-206 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 4 |
| container_start_page | 201 |
| container_title | Ophthalmologica (Basel) |
| container_volume | 236 |
| creator | Giannakaki-Zimmermann, Helena Ebneter, Andreas Munk, Marion R. Wolf, Sebastian Zinkernagel, Martin S. |
| description | Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. Results: Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). Conclusion: A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe. |
| doi_str_mv | 10.1159/000452929 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_452929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1845827480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-2ab7bab7ecb8db0e95920690e9c4cab2dc44efceaf2849de31134b4c8990b3e73</originalsourceid><addsrcrecordid>eNo90UtP3DAQAGCroirbpYfeK-RjOQTGjkPi44pHQaJForvnaOxMQiCPxXa69G_0F9dolz1YY3m-GWk8jH0VcCpEps8AQGVSS_2BzYSSaQLyPD9gM4AUkjTPskP22fsngIi1-MQOZa4h11LN2L_7KdixJ883jzTw35s22Md2aHjtxp4jX7uRO-IDBuQP1LR9RGGMiaUjDByHil-9BorhPbvyb-WLumsNOUvrwNuB_6LxD3o7dej4oqHkgToMVPGfuH27pIYGchjacThiH2vsPH3ZxTlbXV8tL26Su_sftxeLu8QqyEMi0eQmHrKmqAyQzrSEcx0vVlk0srJKUW0Ja1koXVEqRKqMsoXWYFLK0zn7vu0bZ3yZyIeyb72lrsOBxsmXolBZIXNVQKQnW2rd6L2july7tkf3txRQvq2g3K8g2uNd28n0VO3l-59H8G0LntE15PZgV_8fL2yL3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1845827480</pqid></control><display><type>article</type><title>Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration</title><source>Karger Journals</source><source>MEDLINE</source><creator>Giannakaki-Zimmermann, Helena ; Ebneter, Andreas ; Munk, Marion R. ; Wolf, Sebastian ; Zinkernagel, Martin S.</creator><creatorcontrib>Giannakaki-Zimmermann, Helena ; Ebneter, Andreas ; Munk, Marion R. ; Wolf, Sebastian ; Zinkernagel, Martin S.</creatorcontrib><description>Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. Results: Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). Conclusion: A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.</description><identifier>ISSN: 0030-3755</identifier><identifier>EISSN: 1423-0267</identifier><identifier>DOI: 10.1159/000452929</identifier><identifier>PMID: 27907924</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macular Degeneration - complications ; Macular Degeneration - diagnosis ; Macular Degeneration - drug therapy ; Male ; Original Paper ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Recombinant Fusion Proteins - administration & dosage ; Retina - diagnostic imaging ; Retinal Neovascularization - diagnosis ; Retinal Neovascularization - etiology ; Retinal Neovascularization - prevention & control ; Retrospective Studies ; Time Factors ; Tomography, Optical Coherence ; Treatment Outcome ; Visual Acuity</subject><ispartof>Ophthalmologica (Basel), 2016-01, Vol.236 (4), p.201-206</ispartof><rights>2016 S. Karger AG, Basel</rights><rights>2016 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-2ab7bab7ecb8db0e95920690e9c4cab2dc44efceaf2849de31134b4c8990b3e73</citedby><orcidid>0000-0002-7467-7028</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27907924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giannakaki-Zimmermann, Helena</creatorcontrib><creatorcontrib>Ebneter, Andreas</creatorcontrib><creatorcontrib>Munk, Marion R.</creatorcontrib><creatorcontrib>Wolf, Sebastian</creatorcontrib><creatorcontrib>Zinkernagel, Martin S.</creatorcontrib><title>Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration</title><title>Ophthalmologica (Basel)</title><addtitle>Ophthalmologica</addtitle><description>Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. Results: Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). Conclusion: A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.</description><subject>Aged</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - diagnosis</subject><subject>Macular Degeneration - drug therapy</subject><subject>Male</subject><subject>Original Paper</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Retina - diagnostic imaging</subject><subject>Retinal Neovascularization - diagnosis</subject><subject>Retinal Neovascularization - etiology</subject><subject>Retinal Neovascularization - prevention & control</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Visual Acuity</subject><issn>0030-3755</issn><issn>1423-0267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90UtP3DAQAGCroirbpYfeK-RjOQTGjkPi44pHQaJForvnaOxMQiCPxXa69G_0F9dolz1YY3m-GWk8jH0VcCpEps8AQGVSS_2BzYSSaQLyPD9gM4AUkjTPskP22fsngIi1-MQOZa4h11LN2L_7KdixJ883jzTw35s22Md2aHjtxp4jX7uRO-IDBuQP1LR9RGGMiaUjDByHil-9BorhPbvyb-WLumsNOUvrwNuB_6LxD3o7dej4oqHkgToMVPGfuH27pIYGchjacThiH2vsPH3ZxTlbXV8tL26Su_sftxeLu8QqyEMi0eQmHrKmqAyQzrSEcx0vVlk0srJKUW0Ja1koXVEqRKqMsoXWYFLK0zn7vu0bZ3yZyIeyb72lrsOBxsmXolBZIXNVQKQnW2rd6L2july7tkf3txRQvq2g3K8g2uNd28n0VO3l-59H8G0LntE15PZgV_8fL2yL3g</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Giannakaki-Zimmermann, Helena</creator><creator>Ebneter, Andreas</creator><creator>Munk, Marion R.</creator><creator>Wolf, Sebastian</creator><creator>Zinkernagel, Martin S.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7467-7028</orcidid></search><sort><creationdate>20160101</creationdate><title>Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration</title><author>Giannakaki-Zimmermann, Helena ; Ebneter, Andreas ; Munk, Marion R. ; Wolf, Sebastian ; Zinkernagel, Martin S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-2ab7bab7ecb8db0e95920690e9c4cab2dc44efceaf2849de31134b4c8990b3e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - diagnosis</topic><topic>Macular Degeneration - drug therapy</topic><topic>Male</topic><topic>Original Paper</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Retina - diagnostic imaging</topic><topic>Retinal Neovascularization - diagnosis</topic><topic>Retinal Neovascularization - etiology</topic><topic>Retinal Neovascularization - prevention & control</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giannakaki-Zimmermann, Helena</creatorcontrib><creatorcontrib>Ebneter, Andreas</creatorcontrib><creatorcontrib>Munk, Marion R.</creatorcontrib><creatorcontrib>Wolf, Sebastian</creatorcontrib><creatorcontrib>Zinkernagel, Martin S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmologica (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giannakaki-Zimmermann, Helena</au><au>Ebneter, Andreas</au><au>Munk, Marion R.</au><au>Wolf, Sebastian</au><au>Zinkernagel, Martin S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration</atitle><jtitle>Ophthalmologica (Basel)</jtitle><addtitle>Ophthalmologica</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>236</volume><issue>4</issue><spage>201</spage><epage>206</epage><pages>201-206</pages><issn>0030-3755</issn><eissn>1423-0267</eissn><abstract>Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. Results: Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). Conclusion: A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.</abstract><cop>Basel, Switzerland</cop><pmid>27907924</pmid><doi>10.1159/000452929</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7467-7028</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-3755 |
| ispartof | Ophthalmologica (Basel), 2016-01, Vol.236 (4), p.201-206 |
| issn | 0030-3755 1423-0267 |
| language | eng |
| recordid | cdi_karger_primary_452929 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Dose-Response Relationship, Drug Female Follow-Up Studies Humans Intravitreal Injections Macular Degeneration - complications Macular Degeneration - diagnosis Macular Degeneration - drug therapy Male Original Paper Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Retina - diagnostic imaging Retinal Neovascularization - diagnosis Retinal Neovascularization - etiology Retinal Neovascularization - prevention & control Retrospective Studies Time Factors Tomography, Optical Coherence Treatment Outcome Visual Acuity |
| title | Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T12%3A12%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20when%20Switching%20from%20a%20pro%20re%20nata%20Regimen%20to%20a%20Treat%20and%20Extend%20Regimen%20Using%20Aflibercept%20in%20Neovascular%20Age-Related%20Macular%20Degeneration&rft.jtitle=Ophthalmologica%20(Basel)&rft.au=Giannakaki-Zimmermann,%20Helena&rft.date=2016-01-01&rft.volume=236&rft.issue=4&rft.spage=201&rft.epage=206&rft.pages=201-206&rft.issn=0030-3755&rft.eissn=1423-0267&rft_id=info:doi/10.1159/000452929&rft_dat=%3Cproquest_karge%3E1845827480%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1845827480&rft_id=info:pmid/27907924&rfr_iscdi=true |